Nurosym, a medically validated vagus nerve stimulation device from Parasym, offers a noninvasive option for people interested in supporting heart rate variability and recovery through wearable neurotechnology.
London, United Kingdom, September 10, 2026 /PressCable/ -- Per the announcement, Nurosym provides a noninvasive approach to vagus nerve stimulation for people interested in improving heart rate variability as part of their recovery. The CE-marked Class IIa medical device uses Parasym's proprietary AVNT™ waveform, with an earpiece that clips onto the tragus, where the vagus nerve reaches the skin of the ear.
More information is available at https://nurosym.com/
The announcement comes as consumers increasingly use wearable technology to understand recovery, sleep and stress through physiological data. The global heart rate variability biofeedback app market reached $1.8 billion and is projected to grow at a compound annual rate of 12.5%, according to research published by MDPI.
Heart rate variability, or HRV, describes how much the time between heartbeats varies and is a sign of how well the body handles stress. For people monitoring this metric, Nurosym provides a medically validated way to support the nervous system through noninvasive vagus nerve stimulation.
"Recovery is increasingly something people want to understand through measurable information about their bodies," a Nurosym representative said. "Our focus is on making clinically tested vagus nerve stimulation accessible through wearable technology backed by extensive research."
The vagus nerve carries signals between the brain and organs, including the heart, lungs and gut, and plays a large part in how the body handles stress, rest and recovery. Nurosym stimulates the nerve through the ear using gentle electrical pulses delivered through AVNT™.
Research on the technology has examined measurable changes in HRV. In clinical studies, heart rate variability increased by an average of 18%.
Nurosym is the most studied wearable vagus nerve stimulation device, supported by more than 10 years of research and development. Its research programme includes 60+ completed clinical studies and 100+ ongoing clinical studies, with 150+ research partners contributing to the wider evidence base. The technology has also been tested in randomised, placebo-controlled studies.
Nurosym is designed to fit into an ordinary day without surgery, a clinic visit, gel or a prescription. Most people use the device for around 30 minutes, once or twice a day, while working, reading or watching television.
Parasym holds the science, research programme and AVNT patent behind Nurosym. Available in the UK and EU, Nurosym is a CE-marked Class IIa medical device designed to support the nervous system through vagus nerve stimulation at the ear.
Those interested can find additional information at https://nurosym.com/
Disclaimer: Research referenced in this article was conducted using Parasym’s neuromodulation technology under research conditions. Findings relate to specific study populations and should not be interpreted as medical claims or guaranteed individual outcomes. Nurosym is a CE-marked medical device in Europe.
Contact Info:
Name: Michal Valent
Email: Send Email
Organization: Nurosym
Address: 18 Saint Cross Street 4th Floor, London, England EC1N 8UN, United Kingdom
Website: https://nurosym.com/
Source: PressCable
Release ID: 89202991
In case of detection of errors, concerns, or irregularities in the content provided in this press release, or if there is a need for a press release takedown, we strongly encourage you to reach out promptly by contacting [email protected] (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our efficient team will be at your disposal for immediate assistance within 8 hours – resolving identified issues diligently or guiding you through the removal process. We take great pride in delivering reliable and precise information to our valued readers.
